和黄医药(00013.HK):爱优特和达伯舒联合疗法获国家药监局批准用于治疗晚期或转移性肾细胞癌患者

阿斯达克财经
May 22

和黄医药(00013.HK) 与信达生物(01801.HK) 联合宣布,爱优特(ELUNATE,呋喹替尼/fruquintinib)和达伯舒(TYVYT,信迪利单抗注射液/sintilimabinjection)联合疗法的新药上市申请获中国国家药品监督管理局批准,用于治疗既往接受血管内皮生长因子受体-酪氨酸激酶抑制剂(VEGFR-TKI)治疗失败且一线未接受程序性死亡受体-1(PD-1)或程序性...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10